NextCell is a Swedish biopharmaceutical company that specializes in the development of innovative stromal cell therapies, particularly targeting autoimmune and inflammatory diseases. Their lead drug candidate, ProTrans, is designed to treat type 1 diabetes and is based on a patented selection algorithm that enhances the efficacy of mesenchymal stromal cells (MSCs) derived from umbilical cord tissue. ProTrans has shown promising results in clinical trials, demonstrating both safety and the ability to preserve endogenous insulin production in patients. The company is also involved in research for other conditions, such as Crohn's disease and multiple sclerosis, highlighting the broad potential of their stromal cell therapies.

In addition to its therapeutic developments, NextCell operates Cellaviva, Scandinavia's largest private stem cell bank, which allows parents to store their newborns' stem cells for future medical needs. This service capitalizes on the unique opportunity to collect stem cells non-invasively at birth, providing a valuable resource for treating various severe diseases. NextCell's commitment to advancing stem cell technology is further supported by its subsidiary, QVance, which focuses on quality control analytics for cell and gene therapies, thereby enhancing the overall safety and reliability of these advanced treatments.

Sweden

NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma's first product, ProTrans,has started in Novermber 2018.
#nextcellpharma #cellaviva

Immune System Diseases

Metabolic Diseases

Hälsovägen 7, Karolinska Institutet Science Park, Novum 8D, Huddinge, 14157, SE

NextCell

Company Details